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Abstract: Kinase insert domain receptor (KDR) inhibitors have been proved to be very 
effective anticancer agents. Molecular docking, 3D-QSAR methods, CoMFA and CoMSIA 
were performed on pyrrolo[3,2-d]pyrimidine derivatives as non-ATP competitive KDR 
inhibitors (type II). The bioactive conformation was explored by docking one potent 
compound  20  into the active site of KDR in its DFG-out inactive conformation. The 
constructed CoMFA and CoMSIA models produced statistically significant results with the 
cross-validated correlation coefficients q
2 of 0.542 and 0.552, non-cross-validated correlation 
coefficients r
2 of 0.912 and 0.955, and predicted correction coefficients r
2
pred of 0.913 and 
0.897, respectively. These results ensure the CoMFA and CoMSIA models as a tool to 
guide the design of a series of new potent KDR inhibitors. 
Keywords:  CoMFA; CoMSIA; KDR inhibitor; pyrrolo[3,2-d]pyrimidine derivatives; 
Surflex-Dock 
 
1. Introduction 
Angiogenesis, the form of new blood vessels by capillary sprouting from pre-existing vasculatures, 
is a normal process for organ development during embryogenesis, wound healing and female 
reproductive cycling [1,2]. Abnormal regulation of angiogenesis has been shown to get involved in 
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many diseases, such as diabetic retinopathy, psoriasis, rheumatoid arthritis, and cancer. In particular, it 
is widely recognized that the growth and metastasis of solid tumors is dependent on angiogenesis [3,4]. 
Out of the many factors that are involved in angiogenesis, vascular endothelial growth factors (VEGFs) 
are of particular interests [5,6]. The VEGFs are required for vasculogenesis and angiogenic sprouting, 
and act through receptor tyrosine kinase (VEGFR-1, -2, and -3). Among them, VEGF receptor-2 
(VEGFR-2) or kinase insert domain receptor (KDR) play crucial roles in vessel sprouting and new 
vessel initiation in early stage of angiogenesis. 
It is well known that inhibiting of KDR leads to suppression of angiogenesis and tumor growth. A 
number of preclinical and clinical studies have shown that many small-molecule KDR inhibitors are 
capable of inhibiting angiogenesis, tumor progression, and dissemination [7–11]. The vast majority of 
the KDR inhibitors known to date, such as Geﬁtinib, are ATP-competitive and classified as type I 
inhibitors. Such inhibitors target the ATP binding pocket in its active conformation of the activation 
loop. This conformation is normally referred to as DFG “in” based on the position of the conserved 
triad aspartate-phenylalanine-glycine (DFG) at the entrance of the activation loop. Type I  inhibitors 
typically function in the DFG “in” conformation of KDR through hydrogen bonding with the backbone 
residues of the hinge region as well as hydrophobic interactions in and around the adenine region. 
These features, however, make it quite difficult to design highly selective type I inhibitors [12,13].  
In addition, ATP-competitive inhibitors have to compete with high levels of intracellular ATP, leading 
to a significant difference between the in vitro and in vivo activities. In response to these issues,   
non-ATP competitive kinase inhibitors, such as Imatinib have been identified. These inhibitors, i.e., 
type II inhibitors bind to and stabilize an inactive kinase form that features the DFG motif in an “out” 
conformation. The different position of the DFG residues in the “out” form creates a new hydrophobic 
binding pocket that is adjacent to the ATP-binding site. This pocket, also known as the allosteric site, 
is characteristic of kinase in an inactive conformation. Type II inhibitors predominantly occupy the 
ATP binding site, but they also exploit unique hydrogen bonding and hydrophobic interactions with 
the allosteric site. Compared with type I kinase inhibitors, type II inhibitors have several advantages, 
including great cellular potency and improved kinase selectivity. In addition, type II inhibitors, 
because of their interactions with both the ATP pocket and the allosteric site, may provide an avenue 
to overcome the mutations that induce resistance to the other types of inhibitors [14–18]. 
Recently, Oguro et al. reported a set of pyrrolo[3,2-d]pyrimidine derivatives 1–52 (Table 1) as 
potent and selective KDR inhibitors in biochemical and cellular assays [19,20]. These compounds are 
structurally distinct from the ATP-competitive inhibitors, and the X-ray crystallographic analysis has 
shown that compound 27 induces an inactive conformation, in which the diphenylurea moiety occupies 
the hydrophobic pocket created by the conformation change of DFG motif (DFG-out) [19,20]. In the 
present study, to gain further insight into the interactions of these compounds with the KDR, we 
employed the molecular docking-guided three dimensional quantitative structure-activity relationship 
(3D-QSAR) study, comparative molecular field analysis (CoMFA) [21] and comparative molecular 
similarity indices analysis (CoMSIA) [22] to address how steric, electrostatic, hydrophobic and 
hydrogen-bonding interactions modulate the inhibitory activities.  Int. J. Mol. Sci. 2012, 13                 
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Table 1. Structures of compounds 1–52. 
Structure Compound  Substituent 
1-11
N
N N
O
R2
R1
 
  R1 R 2 
1  NHCONHPh H 
2 *  NHCOPh H 
3  CONHPh H 
4  H NHCOPh 
5  H CONHPh 
6 *  H NHCOCH2Ph 
7  H CH2CONHPh 
8  H NHCSNHPh 
9  H 
H
N
N
HN
 
10  H NHCONHMe 
11  H NHCONHPr 
12-14
N
N N
X
HN
HN
O
R
 
 X  R 
12  S H 
13  NH H 
14  N(Me) 3-CF3 
N
N N
N
H
N
H
N
O
CF3
15  
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Table 1. Cont. 
Structure Compound  Substituent 
16-43
N
N N
O
R3
HN
HN
O
R
R4
R1
R2
 
 R  R1 R 2 R 3 R 4 
16 *  Ph H  H  Me  H 
17  2-ClPh H  H  Me  H 
18  3-ClPh H  H  Me  H 
19  4-ClPh H  H  Me  H 
20 *  3-CF3Ph H  H  Me  H 
21  3-BrPh H  H  Me  H 
22  3-FPh H  H  Me  H 
23  3-MePh H  H  Me  H 
24 *  3-CF3Ph Cl  H  Me  H 
25  3-CF3Ph H  Cl  Me  H 
26  3-CF3Ph OMe H  Me  H 
27  3-CF3Ph F  H  Me  H 
28  3-CF3Ph Cl  H  (CH2)2OH H 
29 *  3-CF3Ph Cl  H  (CH2)2OMe H 
30  3-CF3Ph Cl  H  (CH2)2O(CH2)2OH H 
31  3-CF3Ph Cl  H  Me  CH2OH
32  3-CF3Ph Cl  H  Me  CH2OMe
33  3-CF3Ph Cl  H  Me  CMe2OH
34  2-C5H4N Cl  H  Me  H 
35  3-C5H4N Cl  H  Me  H 
36  4-C5H4N Cl  H  Me  H 
37 
N
CF3
Cl H  Me  H 
38 
N
CF3
Cl H  Me  H 
39  N
CF3
Cl H  Me  H 
40 
N
N
CF3
Cl H  Me  H Int. J. Mol. Sci. 2012, 13                 
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Table 1. Cont. 
Structure Compound  Substituent 
16-43
N
N N
O
R3
HN
HN
O
R
R4
R1
R2
 
41 
N
N
H3C
CH3
CH3
Cl H  Me  H 
42 
N
O
H3C
CH3
CH3
Cl H  Me  H 
43 
N
N
H3C
CH3
CH3
CH3
Cl H  Me  H 
44-52
N
N N
O
HN
HN
O
Cl
CF3
R1 R2
 
 R 1 R 2 
44  OMe H 
45  O N H 
46  O N H 
47  N N CH3 H 
48 *  N N O CH3 H 
49 *  H OMe 
50  H  O N
 
51  H  O N
 
52  H  N N O CH3
 
* Test set. 
2. Materials and Methods 
2.1. General 
The crystallographic coordinates of KDR in complex with small-molecule inhibitors were obtained 
from the Brookheaven Protein Databank as entries 2OH4 [23]. All the molecular modeling and 
calculations were performed using Sybyl 7.3 molecular modeling package [24]. 
2.2. Data Sets 
In this study, 52 pyrrolo[3,2-d]pyrimidine derivatives were taken from the work of Oguro et al. [19,20]. 
Their structures and inhibitory activities are listed in Tables 1 and 2. The IC50 values (M) were 
converted to the corresponding pIC50 (= −logIC50). On the basis of the diversity in the structures and 
activities, these 52 compounds were divided into two groups: 44 compounds were used as the training Int. J. Mol. Sci. 2012, 13                 
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set to build the 3D-QSAR models, and 8 compounds that are marked with an asterisk in Table 1 were 
used as the test set to evaluate the predictive power of the developed CoMFA and CoMSIA models. 
Table 2. The experimental pIC50, predicted pIC50 and their residuals of compounds 1–52. 
Compound Exp  pIC50 
COMFA COMSIA 
Pred Resid Pred Resid 
1  5.745 5.194  0.551  5.834 −0.089 
2 *  6.027 5.563  0.464  6.327 −0.300 
3  6.060 5.621  0.439  6.246 −0.185 
4  5.027 4.788  0.239  4.821  0.206 
5  5.000 5.192 −0.192 4.980  0.020 
6 *  5.000 4.808  0.192  5.074 −0.074 
7  5.481 5.698 −0.216 5.285  0.197 
8  5.174 6.042 −0.868 5.129  0.045 
9  5.377 6.029 −0.652 5.156  0.221 
10  5.201 4.852  0.349  5.108  0.093 
11  5.409 5.307  0.102  5.420 −0.011 
12  6.959 7.074 −0.116 6.895  0.063 
13  5.854 5.738  0.116  5.987 −0.133 
14  5.000 5.233 −0.233 5.341 −0.341 
15  8.149 7.729  0.420  7.810  0.339 
16 *  7.481 7.103  0.379  7.189  0.293 
17  6.469 6.863 −0.394 6.927 −0.458 
18  8.387 7.959  0.428  8.187  0.200 
19  7.495 7.201  0.293  7.503 −0.008 
20 *  8.276 8.209  0.066  8.341 −0.066 
21  8.357 7.969  0.387  8.710 −0.354 
22  7.721 7.400  0.321  7.335  0.387 
23  8.569 8.323  0.246  8.153  0.415 
24 *  8.432 8.255  0.177  8.324  0.108 
25  7.523 7.966 −0.443 7.987 −0.464 
26  7.854 8.056 −0.202 8.171 −0.317 
27  8.208 8.176  0.032  8.357 −0.149 
28  8.398 8.812 −0.414 8.386  0.012 
29 *  8.046 8.717 −0.671 8.262 −0.216 
30  8.569 8.977 −0.408 8.308  0.261 
31  8.013 7.987  0.027  7.851  0.162 
32  7.854 7.835  0.019  7.774  0.080 
33  7.745 7.554  0.191  7.701  0.044 
34  6.678 7.047 −0.369 7.042 −0.364 
35  6.638 7.354 −0.716 7.090 −0.451 
36  6.187 6.691 −0.504 6.342 −0.155 
37  8.569 8.307  0.262  8.265  0.303 
38  8.538 8.357  0.181  8.288  0.249 
39  8.420 7.983  0.438  8.084  0.336 Int. J. Mol. Sci. 2012, 13                 
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Table 2. Cont. 
Compound Exp  pIC50 
COMFA COMSIA 
Pred Resid Pred Resid 
40  8.398 7.689  0.709  8.273  0.125 
41  8.119 8.357 −0.238 8.282 −0.163 
42  8.051 8.079 −0.028 7.993  0.058 
43  7.721 8.019 −0.297 8.392 −0.670 
44  8.027 8.013  0.013  7.875  0.152 
45  7.215 7.165  0.050  7.203  0.011 
46  7.721 7.634  0.088  7.805 −0.084 
47  8.032 7.721  0.310  8.072 −0.041 
48 *  7.921 7.706  0.215  7.226  0.695 
49 *  7.699 7.234  0.465  6.911  0.788 
50  7.222 7.135  0.087  7.073  0.149 
51  7.638 7.689 −0.051 7.553  0.086 
52  7.959 7.914  0.044  7.735  0.223 
* Test set. 
2.3. Molecular Docking 
Because the crystal structure of KDR in complex with pyrrolo[3,2-d]pyrimidine was not available 
in the Brookheaven Protein Databank (PDB), the bioactive conformation was simulated by docking 
using Surflex-dock program. The crystallographic coordinates of KDR in complex with its inhibitor, 
which was reported to be in the inactive DFG-out conformation of KDR, were obtained from the  
PDB as entries 2OH4 [23]. Surflex-Dock program [25,26] has been widely used to calculate the 
protein–ligand interactions, and to efficiently predict the active conformations [27–35]. Surflex-Dock 
uses a Protomol-based method and an empirical scoring function to dock a ligand into the binding site 
of a receptor. The Protomol is an idealized representation of a ligand that forms every potential 
interaction with the binding site. Surflex-Dock’s scoring function contains the factors that play crucial 
roles in the ligand-receptor interaction, including hydrophobic, polar, repulsive, entropic and solvation 
terms. In this study, the Protomol was generated using a ligand-based approach. During the Protomol 
generation process, two particular parameters, Protomol_bloat and Protomol_threshold, were specified 
to form the appropriate binding pocket. The former determines how far the site should extend from a 
potential ligand, whereas the latter determines how deep the atomic probes that are used to define the 
Protomol can penetrate into the protein. In the present work, Protomol_bloat and Protomol_threshold 
default values (0 and 0.5, respectively) were used when a reasonable binding pocket was obtained. 
During the docking process, the default values of all the other parameters were assigned. The   
highest-scored conformation of a potent compound 20 based on the Surflex-Dock scoring functions, 
was selected as the final bioactive conformation. 
2.4. Molecular Modeling 
In the 3D-QSAR study, the selection of active conformations is a key step for CoMFA and CoMSIA 
studies. The bioactive conformation of compound 20 was simulated using Surflex-Dock. The docked Int. J. Mol. Sci. 2012, 13                 
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conformation with the highest total score was used as the template to construct the 3D structures of the 
rest compounds in the data set. Structural energy minimization process was performed using the Tripos 
force field with a distance-dependent dielectric and Powell gradient algorithm with a convergence 
criterion of 0.001 kcal/mol. Partial atomic charges were calculated using Gasteiger-Hückel method. 
2.5. Molecular Alignment 
In the 3D-QSAR study, the alignment rule is also a key step. The predictive accuracy of the CoMFA 
and CoMSIA models and the reliability of the contour maps are directly dependent on the structural 
alignment rule. The compounds were aligned by the atomfit to the template 20. The aligned compounds 
are shown in Figure 1. 
Figure 1. Superimposition of compounds in the training and test set. 
 
2.6. CoMFA and CoMSIA Studies 
Standard CoMFA and CoMSIA procedures were performed. A 3D cubic lattice was created 
automatically by extending at least 4 Å beyond all the aligned molecules in X, Y and Z directions with 
2.0 Å grid spacing. The CoMFA steric (Lennard-Jones potential) and electrostatic (Coulomb potential) 
fields at each lattice were calculated using the standard Tripos force field method. A distance dependent 
dielectric constant of 1.0 was used, and an sp
3 hybridized carbon atom with one positive charge and a 
radius of 1.52 Å served as a probe atom to calculate the steric and electrostatic fields. The default 
cutoff value of 30.0 kcal/mol was adopted. 
Compared with CoMFA, CoMSIA methodology has the advantage of exploring the impacts of 
more fields. In addition to the steric (S) and electrostatic (E) fields used in CoMFA, the CoMSIA method 
defines hydrophobic (H), hydrogen bond donor (D), and hydrogen bond acceptor (A) descriptors. The 
CoMSIA fields were derived, according to Klebe et al. [22], from the same lattice box that was used in 
the CoMFA calculations, with a grid spacing of 2 Å and a probe carbon atom with one positive charge 
and a radius of 1.0 Å as implemented in Sybyl. Arbitrary deﬁnition of cutoff limits was not required in 
CoMSIA method, wherein the abrupt changes of potential energy near the molecular surface were 
taken into account in the distance dependent Gaussian type functional form. The default value of 0.3 
was used as the attenuation factor. Int. J. Mol. Sci. 2012, 13                 
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2.7. PLS Regression Analysis and Validation of QSAR Models 
Partial least squares (PLS) approach was used to derive the 3D QSAR models. The CoMFA and 
CoMSIA descriptors were used as independent variables and the pIC50 values were used as dependent 
variables. CoMFA and CoMSIA column filtering was set to 2.0 kcal/mol to improve the signal-to-noise 
ratio. The leave-one-out (LOO) cross-validation was carried out to obtain the optimal number of 
components (N) and the correlation coefficient q
2. The obtained N was then used to derive the final 
QSAR model and to obtain the non-cross-validation correlation coefficient r
2, standard error of 
estimate (SEE), and Fischer (F) ratio value. 
To assess the predictive power of the derived 3D-models, a set of test compounds that had known 
biological activities, was used to validate the obtained models. The predictive correlation r
2
pred value 
was calculated using 
r
2
pred = (SD − PRESS)/SD 
Wherein SD is the sum of the squared deviations between the biological activities of the test 
compounds and the mean activities of the training compounds, and PRESS is the sum of the squared 
deviations between the experimental and the predicted activities of the test compounds. 
3. Results and Discussion 
3.1. Binding Modes of Pyrrolo[3,2-d]pyrimidine Derivatives 
To determine the probable binding conformations of these compounds, Surflex-Dock was used to 
dock one potent compound 20 into the active site of KDR (PDB code: 2OH4). First, the docking 
reliability was validated by a known inhibitor 53 (Figure 2) that was reported to bind in the DFG-out 
inactive conformation of KDR [23]. The co-crystallized 53 was re-docked into the binding site, and the 
docked conformation having the highest total score was selected as the most probable binding 
conformation (Figure 3). The low root mean-square deviation (RMSD) of 0.58 Å between the docked 
and the crystal conformations demonstrated the high reliability of Surflex-dock in reproducing the 
experimentally observed binding mode for these KDR inhibitors. As shown in Figure 3a, redocked 53 
was almost in the same orientation with co-crystallized 53 at the active site of KDR. Therefore, 
Surflex-Dock docking protocol and the used parameters were extended in search for the binding 
conformations of KDR inhibitors. 
Figure 2. Compound 53 from 2OH4 and atom-numbered compound 20. 
 
The binding mode of compound 20 at the active site of KDR in its inactive conformation is shown 
in Figure 3b. It is clear that compound 20 adopts an overall conformation that is very similar to that of Int. J. Mol. Sci. 2012, 13                 
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compound  53, and forms multiple hydrogen bonds with KDR. Specifically, the 1-nitrogen of the 
pyrrolo[3,2-d]pyrimidine subunit forms one hydrogen bond with the backbone-NH of Cys917 in the 
hinge region of KDR at the angle and distance of 130.76° and 3.253 Å, respectively. In the allosteric 
site, the two NH groups of the urea moiety form two hydrogen bonds with the side chain carboxylate 
of Glu883 at the angles of 99.12° and 97.85°, and the distances of 2.566 Å and 2.873 Å, respectively, 
whereas the CO moiety interacts with the backbone-NH of Asp1044 in the DFG motif through 
hydrogen bonding at the angle and distance of 151.02° and of 2.666 Å, respectively. These interactions 
are typical characteristics of the interactions between the inhibitors and the inactive conformation of 
the kinase. In addition, the terminal phenyl moiety occupies the hydrophobic pocket that is formed 
from residues Ile886, Leu887, Ile890, Val896 and Leu1017. 
Figure 3. Binding conformations of (a) co-crystallized (magenta) and re-docked (green) 53 
and (b) docked compound 20 at the active site of kinase insert domain receptor (KDR) in 
the inactive conserved triad aspartate-phenylalanine-glycine (DFG)-out conformation. Key 
residues are displayed and hydrogen bonds are displayed in dotted lines. 
(a) (b) 
3.2. CoMFA and CoMSIA Results 
The CoMFA and CoMSIA 3D-QSAR models were derived from a training set of 44 compounds. 
The statistical results of the CoMFA and CoMSIA 3D-QSAR models are presented in Table 3. The 
CoMFA model gave a cross-validated correlation coefficient q
2 of 0.542, an optimal number of 
principal components (N) of 4 and a non-cross-validated correlation coefficient r
2 of 0.912. The 
corresponding contributions of steric and electrostatic fields were 52.5% and 47.5%, respectively. The 
CoMSIA model gave a cross-validated correlation coefficient q
2 of 0.552, an optimal number of 
principal components of 5 and a non-cross-validated correlation coefficient r
2 of 0.955. The 
corresponding contributions of steric, electrostatic, hydrophobic, hydrogen bond donor and acceptor 
fields were 18.4%, 22.8%, 34.3%, 6.3% and 18.2%, respectively. Both the CoMFA and CoMSIA 
models were satisfactory from the viewpoint of statistical significance. The activities of the 44 training 
compounds were predicted with the constructed CoMFA and CoMSIA models. The predicted pIC50 
values are shown in Table 2 and Figure 4. It can be seen that the predicted pIC50 values were in good 
agreement with the experimental values, indicating that the obtained CoMFA and CoMSIA models 
had strong predictive ability. Int. J. Mol. Sci. 2012, 13                 
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Table 3. Statistical parameters for the CoMFA and CoMSIA models. 
 N  q
2  r
2  SEE F r
2
pred
Field contribution 
S E H D A 
CoMFA 4 0.542 0.912  0.376 100.462 0.913 0.525 0.475 -  -  - 
CoMSIA 5 0.552 0.955 0.272 161.245 0.897 0.184 0.228 0.343 0.063 0.182
q
2: Cross-validated correlation coefficient; r
2: non-cross-validated correlation coefficient; r
2
pred: 
predictive correlation coefficient; SEE: standard error of estimate; F: Fischer ratio; N: optimal 
number of principal components; S: steric field; E: electrostatic field; H: hydrophobic field; D: 
hydrogen bond donor field; A: hydrogen bond acceptor field. 
Figure 4. Graphs of the experimental versus predicted pIC50 values of the training (■) and 
test (▲) compounds from the CoMFA and CoMSIA models. 
 
3.3. Validation of the 3D-QSAR Models 
The predictive powers of the CoMFA and CoMSIA models were validated by the eight test 
compounds. The predicted pIC50 values were found to be in good agreement with the experimental 
data within an acceptable error range (Table 2 and Figure 4). The predictive correction coefficients  
of the CoMFA and CoMSIA models were 0.913 and 0.897, respectively. This result indicates   
that the CoMFA and CoMSIA models may be used to predict the inhibitory activities of novel   
pyrrolo[3,2-d]pyrimidine derivatives as type-II KDR inhibitors. 
3.4. Contour Analysis 
To visualize the results of the CoMFA and CoMSIA models, the 3D coefficient contour maps were 
generated. The CoMFA and CoMSIA results were graphically interpreted by the field contribution 
maps using the STDEV*COEFF field type. The contour maps of CoMFA (steric and electrostatic) and 
CoMSIA (steric, electrostatic, hydrophobic, hydrogen bond donor and acceptor fields) are shown in 
Figures 5 and 6, respectively. Compound 20 was displayed in the map in aid of visualization. All the 
contours represented the default 80% and 20% level contributions for favorable and unfavorable 
regions, respectively, except 90% and 10% level contributions in Figure 6c, respectively. Int. J. Mol. Sci. 2012, 13                 
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Figure 5. CoMFA STDEV*COEFF contour maps. (a) Favorable (green) and unfavorable 
(yellow) steric fields. (b) Electropositive (blue) and electronegative (red) fields. Compound 
20 was overlaid in each map. 
(a) (b) 
Figure 6. STDEV*COEFF contour maps. (a) Favorable (green) and unfavorable (yellow) 
steric fields. (b) Electropositive (blue) and electronegative (red) fields. (c) Favorable 
(yellow) and unfavorable (gray) hydrophobic fields. (d) Favorable (cyan) and unfavorable 
(purple) hydrogen bond donor fields. (e) Favorable (magenta) and unfavorable (red) 
hydrogen bond acceptor fields. Compound 20 was overlaid in each plot. 
(a) 
(b) (c) 
(d) (e) Int. J. Mol. Sci. 2012, 13                 
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3.4.1. CoMFA Contour Maps 
The CoMFA contour maps of the steric and electrostatic fields are shown in Figure 5. In the map of 
steric field, the green contours represent the regions in which bulky groups confer an increase in the 
activity, whereas the yellow ones represent the regions where bulky groups may lead to a decrease in 
the activity. Similarly, in the map of electrostatic field, the blue contours indicate the regions where 
electropositive substitution increases the inhibitory activity, whereas the red contours indicate the 
regions where electronegative substitution increases the activity. 
In the CoMFA steric contour map (Figure 5a), a large green contour near the 3’-position of the 
terminal 3’-trifluoromethylphenyl group of compound 20 suggests that introducing of bulky groups at 
this position would increase the activity. In consistent with this, compounds bearing bulky groups at 
this position, for example, compounds 18, 20, 21 and 23 showed high activities, whereas the ones 
bearing small groups at the same position, for example compounds 16 and 22, showed low activities. 
Large yellow contours near the 4’- and 5’-positions of the terminal 3’-trifluoromethylphenyl group 
suggest that introducing of bulky groups at these positions would decrease the activity. This is in 
agreement with the fact that compounds 44–52 with bulky groups at 4’- or 5’-positions of the terminal 
3’-trifluoromethylphenyl showed decreased activities. In addition, big yellow contours near the 
pyrrolo[3,2-d]pyrimidine subunit suggest that steric bulkiness is unfavorable by the model. When 
pyrrolo[3,2-d]pyrimidine subunit is conjugated to the central phenyl group via a sulfur or nitrogen 
atom (X), the subunit falls into the region of the yellow contour, which suggests that a decrease in the 
inhibitory activity will be observed. For example, sulfur-linked derivative 12 (IC50 = 110 nM) and 
amine-linked derivative 13 (IC50 = 1400 nM) were 3- and 40-fold less active than oxygen-linked 
derivative 16 (IC50 = 33 nM), respectively. 
In the CoMFA electrostatic contour map, a small red contour near the 3’-position of the   
3’-trifluoromethylphenyl group of compound 20 indicates that introduction of electronegative groups 
around this position would increase the inhibitory activity. This, together with the green contour 
discussed above, suggests that electronegative and bulky groups near the 3’-position of the terminal 
phenyl group are favored by the CoMFA model. A blue contour near the 4’-position of the   
3’-trifluoromethylphenyl group indicates that introducing of electropositive groups around this 
position would increase the inhibitory activity. For example, compound 24 with electropositive 
hydrogen at the 4’-position showed higher activity than the corresponding compounds 45–48 with 
electronegative substituents. 
3.4.2. CoMSIA Contour Maps 
The CoMSIA steric and electrostatic contour maps of compound 20 are shown in Figure 6a,b, 
respectively. These contours are quite similar to those of CoMFA. Therefore, our following discussion 
will focus on the hydrophobic, hydrogen bond donor and acceptor fields. 
Figure 6c shows the hydrophobic contour maps in which yellow and gray contours indicate the 
regions where hydrophobic and hydrophilic groups are favored by the model, respectively. A yellow 
contour near the 3’-position of the terminal 3’-trifluoromethylphenyl group indicates that hydrophobic 
substituent at this position would increase the activity. This has been noticed in compounds 18, 20, 21 Int. J. Mol. Sci. 2012, 13                 
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and 23 bearing hydrophobic Cl, CF3, Br and CH3, respectively. These compounds exhibited increased 
activities. This hydrophobic interaction may play a crucial role in improving of the binding affinity, 
since it is also observed in the CoMFA and CoMSIA steric contour maps. The large gray contour near 
the urea indicates that hydrophilic urea at this position is favorable. 
The CoMSIA hydrogen bond donor and acceptor contour plots are shown in Figure 6d,e 
respectively. The cyan contours represent the regions where hydrogen bond-donating groups increase 
the activity, whereas the purple contours represent the regions where hydrogen bond-donating groups 
decrease the activity. Similarly, the magenta contours indicate the regions where hydrogen bond-accepting 
groups increase the inhibitory activity, whereas the red contours indicate the regions where hydrogen 
bond-accepting groups decrease the activity. 
The cyan contours near the NH of urea indicate that hydrogen bond-donating groups are favored. 
This is well consistent with the observations that NH group in this region forms stable hydrogen bonds 
with the residue of Glu883 as hydrogen bond donor, and that the amide derivatives 6 and 7 having a 
CH2 to replace the NH of the urea 16 led to more than 300- and 100-fold decreases in the activities, 
respectively. A large magenta contour located on the carbonyl oxygen of the urea moiety suggests that 
hydrogen bond-accepting groups are favored in this region. This is evident from the fact that thiourea 
derivative 8 was about 100-fold less active than the corresponding urea derivative 16, and that the 
carbonyl oxygen of the urea moiety was engaged in hydrogen bonding interaction with the Asp1044 in 
the DFG motif.  
3.5. Design of New Inhibitors 
As shown above, the CoMFA and CoMSIA have provided detailed insight into the key structural 
requirements for potent activities of the inhibitors of this class. Specifically, the urea plays a crucial 
role in the inhibitory activity—its replacement with thiourea or with an acetamide leads to a complete 
loss of the activity. Substituting of the oxygen linker with sulfur or nitrogen atoms affords less active 
compounds. Introducing of appropriately bulky and strongly hydrophobic groups at the 3’-position of 
the terminal phenyl group may significantly increase the activity. To demonstrate the practical values 
of these structure-activity relationships, a series of new inhibitors were designed and their pIC50 values 
were predicted with the established CoMFA and CoMSIA models (Table 4). 
Table 4. Structures and predicted pIC50 values of newly designed derivatives. 
N
N N
O
H
N
H
N
O
R1
R
 
Compound R  R1 
Predicted pIC50 
CoMFA CoMSIA 
D1 Cl 
N
CF3
8.162 8.052 Int. J. Mol. Sci. 2012, 13                 
 
 
2401
Table 4. Cont. 
Compound R  R1 
Predicted pIC50 
CoMFA CoMFA 
D2 Cl 
N
CF3
8.463 8.049 
D3 Cl  N
CF3
7.972 7.876 
D4 Cl 
N
CF3
Me 8.373 9.102 
D5 Cl 
N
CF3
Me 8.124 8.696 
D6 Cl 
N
Cl
Me 7.797 8.405 
D7 H  3-EtPh  8.216  8.507 
D8 H  3-CH2CF3Ph 8.378 8.891 
D9 H  3,4-2CH3Ph 8.193  8.609 
D10 H  3-CF3,4-CH3Ph 8.234  8.837 
D11 Cl  3-CH3Ph 7.993  8.096 
D12 Cl 3,4-2CH3Ph 8.170  8.582 
D13 Cl  3-CF3,4-CH3Ph 8.258  8.814 
D14 Cl  3-ClPh  7.898  8.245 
D15 Cl  3-Cl,4-CH3Ph 8.191 8.731 
4. Concluding Remarks 
In this study, 3D-QSAR analyses, CoMFA and CoMSIA, have been applied to a set of recently 
synthesized pyrrolo[3,2-d]pyrimidine derivatives as type II KDR inhibitors. The binding mode of the 
template molecule 20  was clarified by Surflex-dock. The CoMFA and CoMSIA models showed 
statistically significant results in terms of cross-validated coefficients and conventional coefficients. 
Their predictive capabilities were verified by the test compounds. The derived CoMFA and CoMSIA 
models showed predictive cross-validated coefficients of 0.913 and 0.897, respectively, and the 
activities of the training and test compounds were predicted with good accuracy. Based on the obtained 
structure-activity relationships, a series of new inhibitors were designed to have excellent activities 
that were predicted with the developed CoMFA and CoMSIA models. Thus, these models may be 
expected to serve as a tool to guide the future rational design of pyrrolo[3,2-d]pyrimidine-based novel 
type II KDR inhibitors with potent activities. Int. J. Mol. Sci. 2012, 13                 
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